Skip to main content
PepStack
Hormone · Profile

Cortisol

Hydrocortisone · Compound F · Cortef

Adrenal HormonesApproved
MW
362.5g/mol
Formula
C21H30O5

Cortisol is a glucocorticoid hormone produced by the adrenal cortex, playing a crucial role in the body's response to stress and maintaining homeostasis. Researchers primarily study cortisol to understand its effects on metabolism, immune response, and its role in various health conditions, including adrenal insufficiency and stress-related disorders. Key findings indicate that cortisol levels exhibit a diurnal rhythm, with alterations linked to various health issues, such as obesity, depression, and cardiovascular risk. Additionally, clinical evidence suggests that salivary measurements of cortisol can provide valuable insights into adrenal function and stress responses, offering a non-invasive alternative to traditional blood tests. Current research is focused on optimizing cortisol replacement therapies and understanding its complex interactions with memory and emotional processing, highlighting its significance in both clinical and psychological contexts.

Overview

Übersicht

Cortisol, also known as hydrocortisone, Compound F, or Cortef, is an endogenous glucocorticoid hormone produced by the adrenal cortex. It belongs to the adrenal hormones category and plays a crucial role in various physiological processes. Cortisol is synthesized from cholesterol and is released in response to stress and low blood-glucose concentration. It is also available in synthetic form for therapeutic use. Researchers have extensively studied cortisol's role in regulating metabolism, immune response, and stress response. It is involved in the pathogenesis of conditions such as bronchopulmonary dysplasia in preterm infants and is used in replacement therapy for adrenal insufficiency. Cortisol's mechanism of action involves binding to glucocorticoid receptors, influencing gene expression, and modulating inflammatory and immune responses. Researchers have observed that cortisol acts as a secondary messenger in the hypothalamo-pituitary-adrenal (HPA) axis, coordinating the body's response to stress. Pharmacokinetically, cortisol has a circulating half-life of approximately 70 minutes. It is metabolized primarily in the liver and excreted in urine. Oral bioavailability is limited due to first-pass metabolism. Clinically, cortisol is used in the treatment of adrenal insufficiency and as an anti-inflammatory agent. It is approved by regulatory agencies such as the FDA for various indications. Researchers have found that novel formulations, such as delayed and sustained release hydrocortisone, offer improved therapeutic outcomes by better mimicking physiological cortisol rhythms.

Chemical profile

Chemische Struktur

Chemical structure of Cortisol
FormelC21H30O5
Molekulargewicht362.5g/mol
CAS-Nummer50-23-7
PubChem CID5754
Mechanism

Wirkmechanismus

Cortisol acts primarily on glucocorticoid receptors, which are part of the nuclear receptor family. Upon binding, it influences gene transcription, leading to modulation of inflammatory and immune responses. This cascade affects various physiological processes, including metabolism and stress response.

Mechanism

Signalweg

Cortisol primarily exerts its effects through the glucocorticoid receptor (GR), which, upon binding to cortisol, translocates to the nucleus and regulates gene expression by interacting with glucocorticoid response elements (GREs). This action activates various signaling pathways, including the modulation of the HPA axis and the cAMP/PKA pathway, influencing processes such as inflammation control, stress response, and metabolic regulation. While the overall mechanism is well-characterized, some aspects of cortisol's effects on specific cellular signaling and interactions remain incompletely understood.

Half-Life & Pharmacokinetics

ENEndogenous

Circulating half-life ~70 minutes

POOral

Poor bioavailability due to first-pass metabolism

Hydrocortisone formulations may vary in bioavailability and half-life based on the route of administration and formulation type.

Storage

Temperature

Store at room temperature (15-30C)

Light

Protect from light

Form

Aqueous solution: use within specified period after opening

Notes

Ensure proper sealing of containers to prevent contamination and degradation.

Solubility

Löslichkeit

Cortisol is sparingly soluble in water, but soluble in ethanol and other organic solvents.

Legal Status

🇩🇪DE

Verschreibungspflichtig (prescription only), not listed under BtMG.

🇺🇸US

FDA approved for various indications; prescription required.

🇦🇺AU

TGA Schedule 4 (S4): Prescription only medicine.

🇬🇧UK

Prescription only medicine (POM) under MHRA regulation.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Open Questions

Offene Forschungsfragen

Current evidence is limited regarding the long-term effects of early low-dose hydrocortisone on neurodevelopmental outcomes in extremely preterm infants, necessitating larger randomized controlled trials to clarify potential risks and benefits. Additionally, further research is needed to understand the mechanisms by which cortisol influences hippocampal function and memory encoding, particularly in diverse populations with varying stress responses. There is also a need for studies that explore the efficacy of novel hydrocortisone formulations in mimicking physiological cortisol rhythms and their impact on quality of life in patients with adrenal insufficiency.

61 Research Publications

1,332

Total Citations

34

Human/RCT

2.2

Avg. Influence

2023

Latest

Sort
Filter
#01

Modified-release hydrocortisone to provide circadian cortisol profiles.

HumanInfluence6.0
293
The study demonstrated that modified-release hydrocortisone can replicate physiological cortisol profiles, suggesting a potential improvement in glucocorticoid replacement therapy for individuals with adrenal insufficiency.
#02

Salivary cortisol and cortisone in the clinical setting.

Blair Joanne, et al. · Current opinion in endocrinology, diabetes, and obesity · 2017

ReviewInfluence7.0
104
Researchers observed that salivary cortisone is a superior marker for assessing cortisol levels, particularly during low serum cortisol states and hydrocortisone therapy.

Key findings

  1. 01Salivary measurements detect only free hormones and can be taken easily during daily routines.
  2. 02Salivary cortisone is a better marker than salivary cortisol for low serum cortisol levels.
  3. 03Salivary biomarkers are more accurate for assessing adrenal reserve compared to serum cortisol.
#03

Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Case ReportInfluence5.0
100
The study demonstrated that the bioavailability of oral hydrocortisone is high in pediatric patients with congenital adrenal hyperplasia, potentially leading to supraphysiological cortisol concentrations.
#04

Hydrocortisone down-regulates the tumor suppressor gene BRCA1 in mammary cells: a possible molecular link between stress and breast cancer.

AnimalInfluence1.0
74
Researchers observed that hydrocortisone down-regulates the expression of the breast cancer susceptibility gene BRCA1 in mouse mammary cells, suggesting a potential molecular link between stress and breast cancer development.
#05

Human studies on hypothalamo-pituitary-adrenal (HPA) axis.

Liyanarachchi Kamani, et al. · Best practice & research. Clinical endocrinology & metabolism · 2017

ReviewInfluence3.0
70
The study demonstrated that disruptions in cortisol rhythm are associated with metabolic disturbances and increased health risks in humans, particularly in conditions like Cushing's syndrome and adrenal insufficiency.

Key findings

  1. 01Shift work and certain health conditions disrupt the normal cortisol rhythm.
  2. 02Higher cortisol levels are linked to serious health risks, including metabolic issues.
  3. 03New therapies aim to better mimic the natural cortisol rhythm to improve patient outcomes.
#06

Novel strategies for hydrocortisone replacement.

ReviewInfluence2.0
60
Researchers observed that novel circadian hydrocortisone therapies may improve biochemical control and quality of life in patients with adrenal insufficiency.
#07

Corticosteroid-binding globulin regulates cortisol pharmacokinetics.

In VitroInfluence3.0
59
Researchers observed that corticosteroid-binding globulin significantly affects cortisol pharmacokinetics, with variations leading to altered total serum cortisol disposition without affecting free serum cortisol levels.
#08

Systemic hydrocortisone/cortisol induces allergic skin reactions in presensitized subjects.

Case Report
58
The study demonstrated that systemic hydrocortisone can elicit allergic skin reactions in presensitized individuals, indicating potential risks associated with hydrocortisone therapy.
#09

Value of free cortisol measurement in systemic infection.

Review
45
The study demonstrated that free cortisol levels correlate more closely with sepsis severity than total cortisol, suggesting that free cortisol measurement may guide hydrocortisone supplementation in systemic infections.
#10

Central adrenal insufficiency: open issues regarding diagnosis and glucocorticoid treatment.

ReviewInfluence4.0
42
The study demonstrated that dynamic testing is essential for diagnosing central adrenal insufficiency, as basal cortisol levels alone may not be sufficient.

Clinical Trials (27)

Preclinical
Phase I
Phase II
Phase III
Approved

27

Total Trials

6,177

Total Enrolled

Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS

NCT01540812COMPLETED
Sponsor

PETHEMA Foundation

Enrollment

418

Started

2012

Primary outcome

Overall response rate

Acute Lymphoblastic Leukemia

Early Intravenous Hydrocortisone in Sepsis

NCT06217939RECRUITING
Sponsor

Siriraj Hospital

Enrollment

230

Started

2024

Primary outcome

28-day mortality

Sepsis SevereShock, Septic

Applied Social Neuroscience: the Building Resilience Among Women Project

Sponsor

Ximena Goldberg

Enrollment

172

Started

2019

Primary outcome

Salivary cortisol

Violence, DomesticStress Related DisorderDepressive Disorder

The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight Regulation

NCT00688987COMPLETED
Sponsor

Oregon Health and Science University

Enrollment

24

Started

2000

Primary outcome

Amounts of intra-abdominal fat and total fat at the end of the treatment period for each cortisol dose.

ObesityAddison's Disease

Patient Self-administration of Cortisol for Cortisol-responding Disorders in Men and Women Over the Age of 17

NCT03558971Phase 4COMPLETED
Sponsor

Helen Foundation

Enrollment

2,430

Started

2000

Primary outcome

Participant evaluation of disease symptom intensity

Rheumatic Diseases

Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency

NCT05435781Phase 4RECRUITING
Sponsor

Marianne Christina Klose

Enrollment

250

Started

2022

Primary outcome

ecological momentary assessments (EMA) of the Multidimensional Fatigue Inventory (MFI-20) General Fatigue scale, adjusted for EMA

Adrenal InsufficiencyPolymyalgia RheumaticaGiant Cell Arteritis

Vitamin C, Vitamin B1 and Steroid in Sepsis

NCT04039815Phase 4UNKNOWN
Sponsor

Far Eastern Memorial Hospital

Enrollment

80

Started

2019

Primary outcome

The primary endpoint was the hospital survival.

Sepsis, Severe

Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance

NCT07494084Phase 4NOT_YET_RECRUITING
Sponsor

Washington State University

Enrollment

48

Started

2026

Primary outcome

Insulin resistance-Minimal Model (Si)

Shift Work ScheduleCircadian RhythmInsulin ResistanceCircadian Misalignment

Reversal of Acute β-Blocker Induced Bronchoconstriction

NCT01070225Phase 4COMPLETED
Sponsor

University of Dundee

Enrollment

14

Started

2010

Primary outcome

To establish whether acute β-blockade influences the ability to achieve airway reversibility and recovery with systemic corticosteroids and nebulised bronchodilators following histamine challenge in mild to moderate asthmatics.

Asthma

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650Phase 3RECRUITING
Sponsor

Merck Sharp & Dohme LLC

Enrollment

1,314

Started

2023

Primary outcome

Radiographic Progression-Free Survival (rPFS)

Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms

Stress Hydrocortisone In Pediatric Septic Shock

NCT03401398Phase 3RECRUITING
Sponsor

Jerry Zimmerman

Enrollment

500

Started

2019

Primary outcome

New or progressive multiple organ dysfunction syndrome as assessed utilizing the Pediatric Logistic Organ Dysfunction (PELOD-2) instrument.

Septic Shock

Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED-AID Study)

NCT03936517Phase 3UNKNOWN
Sponsor

Imperial College London

Enrollment

44

Started

2019

Primary outcome

Change in concentration of Osteocalcin

Adrenal Insufficiency

Corticosteroid Intralesional Injection as an Alternative Treatment in Oral Pyogenic Granuloma in the Esthetic Zone.

NCT05534334Phase 2/3UNKNOWN
Sponsor

Beni-Suef University

Enrollment

30

Started

2022

Primary outcome

Remaining width of the attached gingiva

Oral Pyogenic Granuloma

Early Versus Conventional Cessation of Hydrocortisone in Septic Shock

NCT05818826Phase 2UNKNOWN
Sponsor

Mahidol University

Enrollment

160

Started

2023

Primary outcome

Composite adverse events of early versus conventional cessation of hydrocortisone

Septic ShockAdverse EventHydrocortisoneHyperglycemiaHypernatremiaMuscle WeaknessSuperimposed Infection

Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids

NCT03335774Phase 2COMPLETED
Sponsor

Nivagen Pharmaceuticals Inc.

Enrollment

103

Started

2019

Primary outcome

Reduction in Swelling

Internal Hemorrhoids

A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone

NCT05607901Phase 2COMPLETED
Sponsor

Tanta University

Enrollment

100

Started

2022

Primary outcome

To compare the impact of topical tacrolimus ointment to topical hydrocortisone cream by measuring inflammatory cytokine levels in the blood.

Dermatologic Disease

Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00460031Phase 2COMPLETED
Sponsor

Case Comprehensive Cancer Center

Enrollment

34

Started

2006

Primary outcome

Number of Patients With a Partial Response, Progressive Disease, or Stable Disease Based on Prostate-Specific Antigen (PSA) or Measurable Disease

Prostate Cancer

Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy

NCT00895310Phase 2COMPLETED
Sponsor

University of California, Davis

Enrollment

30

Started

2009

Primary outcome

Prostate Specific Antigen (PSA) Response (>50% Reduction From Baseline)

Prostate Cancer

Medihoney® Derma Cream Treatment for Mild to Moderate Atopic Dermatitis in Children Study

NCT05276323Phase 2COMPLETED
Sponsor

Soroka University Medical Center

Enrollment

30

Started

2020

Primary outcome

response rate

Atopic Dermatitis

Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT

NCT00084838Phase 2COMPLETED
Sponsor

Dana-Farber Cancer Institute

Enrollment

25

Started

2003

Primary outcome

2-yr Overall Survival

Central Nervous System Tumor, Pediatric

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

NCT02481310Phase 1/2UNKNOWN
Sponsor

Northwestern University

Enrollment

38

Started

2015

Primary outcome

To Determine the Recommended Phase II Dose (RP2D) of Ixazomib in Combination With DA-EPOCH-R.

Adult Burkitt LymphomaB-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt LymphomaDiffuse Large B-Cell LymphomaMYC Gene MutationPlasmablastic Lymphoma

Effects of Fludrocortisone and Hydrocortisone in Healthy Volunteers With Aldosterone Induced Suppression

NCT00673270Phase 1/2TERMINATED
Sponsor

Rennes University Hospital

Enrollment

13

Started

2008

Primary outcome

Phenylephrine-mean arterial pressure dose-response relationship

Renin Angiotensin

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

NCT05476770Phase 1RECRUITING
Sponsor

Therapeutic Advances in Childhood Leukemia Consortium

Enrollment

54

Started

2022

Primary outcome

Occurrence of dose limiting toxicity (DLT) during cycle 1 of therapy

Hematologic MalignancyAMLALLBPDCNMDSLymphoblastic LymphomaLymphoma, B-CellLymphoma, T-CellHodgkin LymphomaMixed Phenotype Acute LeukemiaAcute Undifferentiated Leukemia

An Investigational Study of Hydrocortisone

NCT01960530Phase 1COMPLETED
Sponsor

Neurocrine UK Limited

Enrollment

14

Started

2013

Primary outcome

Maximum Serum Concentration (Cmax)

Adrenal Insufficiency

Early Blood Pressure Management in Extremely Premature Infants

NCT00874393Phase 1COMPLETED
Sponsor

NICHD Neonatal Research Network

Enrollment

10

Started

2009

Primary outcome

Enrollment and completion of 60 infants

Infant, NewbornInfant, Low Birth WeightInfant, Small for Gestational AgeInfant, PrematureHypotensionBlood Pressure

Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

NCT03349281Phase 1COMPLETED
Sponsor

Julio Barredo, MD

Enrollment

6

Started

2019

Primary outcome

Rate of Toxicity in Study Participants Receiving Protocol Therapy

Refractory Acute Lymphoblastic LeukemiaRelapsed Acute Lymphoblastic Leukemia

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

NCT01186328Phase 1TERMINATED
Sponsor

Therapeutic Advances in Childhood Leukemia Consortium

Enrollment

6

Started

2010

Primary outcome

Maximum Tolerated Dose of EZN-3042

Lymphoblastic Leukemia, AcuteLymphoblastic Leukemia, Acute, ChildhoodLeukemia, Lymphoblastic, Acute, T CellLeukemia, Lymphoblastic, Acute

Track your hormone research in PepStack

Log cycles, set reminders and visualize serum levels.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer